---
name: literature-search
description: | Use when this capability is needed.
metadata:
  author: huifer
---

# Literature Search Skill

Search and analyze scientific literature for drug discovery insights.

## Quick Start

```
/pubmed EGFR resistance
/literature-search "KRAS G12C" --year 2023-2024
Find recent papers on PROTAC technology
What are the key publications on ADC toxicity?
```

## What's Included

| Feature | Description |
|---------|-------------|
| **Smart Search** | Automatic query optimization and expansion |
| **Summarization** | Key findings extraction from abstracts |
| **Trend Analysis** | Publication trends over time, hot topics |
| **Key Papers** | High-impact identification by citations |
| **Preprints** | bioRxiv/arXiv integration for early access |
| **Related Work** | Citation network exploration |

## Data Sources

| Source | Coverage | API |
|--------|----------|-----|
| PubMed | 35M+ citations | E-utilities |
| PubMed Central | 9M+ full-text | E-utilities |
| bioRxiv | 200K+ preprints | API |
| medRxiv | 80K+ preprints | API |
| arXiv | 2M+ preprints | API |

## Output Structure

```markdown
# Literature Search: EGFR Resistance

## Summary
Found **847 papers** (2020-2024). Key trends: 3rd-gen TKI resistance mechanisms,
C797S mutation targeting, combination strategies, and 4th-generation TKIs.

## Publication Trend
```
2020: 127 papers
2021: 156 papers  ↑23%
2022: 183 papers  ↑17%
2023: 198 papers  ↑8%
2024 (YTD): 183 papers
```
**Growth Rate**: +13% CAGR
**Hot Topic Alert**: C797S mutation papers up 340% (2022-2024)

## Key Papers (Top 10)

### 1. Osimertinib resistance mechanisms (Nature Medicine, 2023)
- **Citation**: 234
- **Journal Impact Factor**: 82.9
- **Key Finding**: C797S mutation accounts for 40% of 3rd-gen resistance;
  MET amplification 35%, HER2 amplification 15%
- **Authors**: Wang et al. (Memorial Sloan Kettering)

### 2. Fourth-generation EGFR TKIs (Cancer Cell, 2024)
- **Citation**: 89
- **Key Finding**: BLU-945 shows activity against C797S in xenograft models;
  clinical data promising

[... 8 more key papers ...]

## Research Themes

### Theme 1: Resistance Mechanisms (45% of papers)
| Sub-theme | Paper Count | Growth |
|-----------|-------------|--------|
| C797S mutation | 127 | +340% |
| MET amplification | 98 | +180% |
| Phenotypic transformation | 67 | +120% |

### Theme 2: Combination Strategies (25% of papers)
| Combination | Evidence Level |
|-------------|----------------|
| EGFR + MET TKI | Phase III positive |
| EGFR + Chemotherapy | Standard of care |
| EGFR + Anti-angiogenic | Mixed results |

### Theme 3: Novel Modalities (15% of papers)
| Modality | Paper Count | Status |
|----------|-------------|--------|
| 4th-gen TKI | 43 | 5 in clinic |
| Bispecific antibodies | 28 | 3 in clinic |
| ADC approaches | 34 | Early |
| PROTAC | 19 | Preclinical |

### Theme 4: Biomarker Discovery (10% of papers)
- ctDNA monitoring
- Early detection of resistance
- Patient stratification

### Theme 5: CNS Metastases (5% of papers)
- Brain penetration strategies
- Intracranial efficacy

## Top Journals

| Journal | Papers | % | Avg IF |
|---------|--------|---|--------|
| Clinical Cancer Research | 78 | 9% | 10.2 |
| J Thorac Oncol | 67 | 8% | 20.1 |
| Nat Commun | 54 | 6% | 16.6 |
| Ann Oncol | 45 | 5% | 50.5 |

## Leading Institutions

| Institution | Papers | Key Collaborators |
|-------------|--------|-------------------|
| Memorial Sloan Kettering | 67 | Dana-Farber, Mass General |
| Dana-Farber Cancer Institute | 54 | MSK, MD Anderson |
| MD Anderson | 48 | DFCI, MSK |
| AstraZeneca | 43 | Academic partners |

## Key Clinical Trials Referenced

| Trial | Phase | Finding | Citation |
|-------|-------|---------|----------|
| FLAURA2 | III | Chemo combo superior | 234 papers |
| MARIPOSA | III | Lazertinib vs osimertinib | 156 papers |
| SAVANNAH | II | MET combo resistance | 89 papers |

## Emerging Keywords (2023-2024)
| Keyword | Frequency | Growth |
|---------|-----------|--------|
| C797S | 234 | +450% |
| Fourth-generation | 189 | +380% |
| Bispecific | 156 | +220% |
| Neoantigen | 98 | +180% |
| Liquid biopsy | 87 | +150% |

## Knowledge Gaps Identified
1. Long-term resistance beyond C797S
2. Optimal combination sequencing
3. Biomarkers for patient selection
4. Quality of life endpoints
```

## Examples

### Basic Search
```
/pubmed EGFR resistance
/literature KRAS inhibitors
Search for ADC toxicity papers
```

### Time-Bounded Search
```
/pubmed "KRAS G12C" --year 2023-2024
/literature PROTAC --since 2022-06
Papers from last 6 months on GLP-1
```

### Focused Search
```
/pubmed EGFR --focus clinical
/literature "bispecific antibodies" --focus preclinical
Search reviews only on CAR-T toxicity
```

### Comparison Search
```
Compare literature on 1st vs 2nd gen EGFR TKIs
/pubmem KRAS vs NRAS vs HRAS clinical data
```

### Trend Analysis
```
What are the emerging trends in ADC research?
/literature trends obesity drugs --last 5years
```

## Search Operators

| Operator | Usage | Example |
|----------|-------|---------|
| `AND` | Combine terms | `EGFR AND resistance` |
| `OR` | Either term | `TKI OR antibody` |
| `NOT` | Exclude | `EGFR NOT lung` |
| `*` | Wildcard | `resist*` |
| `""` | Phrase | `"C797S mutation"` |
| `[]` | MeSH terms | `EGFR[MeSH]` |

## Running Scripts

```bash
# Basic search
python scripts/pubmed_search.py "EGFR resistance" --output results.json

# With date range
python scripts/pubmed_search.py "KRAS G12C" --start 2023-01-01 --end 2024-12-31

# Include full-text
python scripts/pubmed_search.py "PROTAC" --full-text --max 50

# Trend analysis
python scripts/pubmed_search.py "ADC toxicity" --trend --years 5

# Preprints only
python/scripts/pubmed_search.py "mRNA vaccines" --preprints
```

## Requirements

```bash
pip install requests pandas biopython
```

## Additional Resources

- [PubMed E-utilities API](reference/pubmed-api.md)
- [Search Strategy Guide](reference/search-strategies.md)
- [Data Extraction Scripts](reference/extraction-scripts.md)

## Best Practices

1. **Start broad, then narrow**: Search broad terms first
2. **Use quotes for phrases**: `"C797S mutation"` not `C797S mutation`
3. **Check recent first**: Sort by publication date for current research
4. **Review high-impact**: Check citation count for key papers
5. **Include preprints**: For cutting-edge developments

## Common Pitfalls

| Pitfall | Solution |
|---------|----------|
| Too many results | Add specific terms, date range |
| Too few results | Use synonyms, expand search |
| Missing recent | Check preprint servers |
| Not specific enough | Use MeSH terms |
| Overlap | Remove duplicates before analysis |

## Output Options

| Format | Description |
|--------|-------------|
| Summary (default) | Key insights, trends, top papers |
| Full | All papers with abstracts |
| BibTeX | Citation export |
| CSV | Data analysis ready |
| Markdown | Report format |

---
> Converted and distributed by [TomeVault](https://tomevault.io/claim/huifer) — claim your Tome and manage your conversions.
<!-- tomevault:4.0:skill_md:2026-04-13 -->
